News
I rate Bio-Rad (NYSE:BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback